123 related articles for article (PubMed ID: 38606933)
41. Leucine-rich repeat-containing G protein-coupled receptor 4 (Lgr4) is necessary for prostate cancer metastasis via epithelial-mesenchymal transition.
Luo W; Tan P; Rodriguez M; He L; Tan K; Zeng L; Siwko S; Liu M
J Biol Chem; 2017 Sep; 292(37):15525-15537. PubMed ID: 28768769
[TBL] [Abstract][Full Text] [Related]
42. Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism.
Teichert F; Verschoyle RD; Greaves P; Edwards RE; Teahan O; Jones DJ; Wilson ID; Farmer PB; Steward WP; Gant TW; Gescher AJ; Keun HC
Prostate; 2008 Jul; 68(10):1035-47. PubMed ID: 18459103
[TBL] [Abstract][Full Text] [Related]
43. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
[TBL] [Abstract][Full Text] [Related]
44. Interception Targets of
Tang SN; Jiang P; Kim S; Zhang J; Jiang C; Lü J
Cancer Prev Res (Phila); 2021 Jun; 14(6):635-648. PubMed ID: 33648943
[TBL] [Abstract][Full Text] [Related]
45. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
Dzojic H; Loskog A; Tötterman TH; Essand M
Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482
[TBL] [Abstract][Full Text] [Related]
46. Surgical orthotopic implantation allows high lung and lymph node metastatic expression of human prostate carcinoma cell line PC-3 in nude mice.
An Z; Wang X; Geller J; Moossa AR; Hoffman RM
Prostate; 1998 Feb; 34(3):169-74. PubMed ID: 9492844
[TBL] [Abstract][Full Text] [Related]
47. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.
Huss WJ; Gray DR; Tavakoli K; Marmillion ME; Durham LE; Johnson MA; Greenberg NM; Smith GJ
Neoplasia; 2007 Nov; 9(11):938-50. PubMed ID: 18030362
[TBL] [Abstract][Full Text] [Related]
48. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
[TBL] [Abstract][Full Text] [Related]
49. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
50. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.
Jeet V; Ow K; Doherty E; Curley B; Russell PJ; Khatri A
Prostate; 2008 Apr; 68(5):548-62. PubMed ID: 18247402
[TBL] [Abstract][Full Text] [Related]
51. Macrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer development but increases metastases in TRAMP prostate cancer prone mice.
Husaini Y; Qiu MR; Lockwood GP; Luo XW; Shang P; Kuffner T; Tsai VW; Jiang L; Russell PJ; Brown DA; Breit SN
PLoS One; 2012; 7(8):e43833. PubMed ID: 22952779
[TBL] [Abstract][Full Text] [Related]
52. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
[TBL] [Abstract][Full Text] [Related]
53. Magnetic resonance imaging and histopathological characterization of prostate tumors in TRAMP mice as model for pre-clinical trials.
Degrassi A; Russo M; Scanziani E; Giusti A; Ceruti R; Texido G; Pesenti E
Prostate; 2007 Mar; 67(4):396-404. PubMed ID: 17187397
[TBL] [Abstract][Full Text] [Related]
54. Capsaicin reduces the metastatic burden in the transgenic adenocarcinoma of the mouse prostate model.
Venier NA; Yamamoto T; Sugar LM; Adomat H; Fleshner NE; Klotz LH; Venkateswaran V
Prostate; 2015 Sep; 75(12):1300-11. PubMed ID: 26047020
[TBL] [Abstract][Full Text] [Related]
55. Models of neuroendocrine prostate cancer.
Berman-Booty LD; Knudsen KE
Endocr Relat Cancer; 2015 Feb; 22(1):R33-49. PubMed ID: 25349195
[TBL] [Abstract][Full Text] [Related]
56. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
Lee AR; Gan Y; Tang Y; Dong X
EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395
[TBL] [Abstract][Full Text] [Related]
57. Development of a novel castration-resistant orthotopic prostate cancer model in New Zealand White rabbit.
Wang Y; Abenojar EC; Wang J; de Leon AC; Tavri S; Wang X; Gopalakrishnan R; Walker E; MacLennan GT; Giles A; Czarnota GJ; Basilion JP; Exner AA
Prostate; 2022 May; 82(6):695-705. PubMed ID: 35167141
[TBL] [Abstract][Full Text] [Related]
58. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
59. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
Gupta S; Adhami VM; Subbarayan M; MacLennan GT; Lewin JS; Hafeli UO; Fu P; Mukhtar H
Cancer Res; 2004 May; 64(9):3334-43. PubMed ID: 15126378
[TBL] [Abstract][Full Text] [Related]
60. 2,3,7,8-Tetrachlorodibenzo-p-dioxin has both pro-carcinogenic and anti-carcinogenic effects on neuroendocrine prostate carcinoma formation in TRAMP mice.
Moore RW; Fritz WA; Schneider AJ; Lin TM; Branam AM; Safe S; Peterson RE
Toxicol Appl Pharmacol; 2016 Aug; 305():242-249. PubMed ID: 27151233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
